PFIZER SAYS COVID-19 PILL CUT HOSPITAL, DEATH RISK BY 90%

On Friday, Pfizer Inc. announced that its experimental pill for Covid-19 cut rates of hospitalization and death by upto 90%, in high risk adults as the manufacturer joins the race to bring accessible medications in the market, against Coronavirus, reported Associated Press. 

 

Pfizer said it will ask international regulators like FDA to authorise its pills as soon as possible after experts recommended a halt to the company’s study based on its successful results. Once the drugmaker applies for approval, the FDA could take weeks or months to authorise the medication. Currently, all covid-19 treatments in the United States and most countries are administered intravenously or through injections. “We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer.

On Friday Pfizer released the results of its study of 775 adults, patients who received the drug along with another antiviral shortly after showing symptoms had an 89% reduction in their ‘rate of hospitalisation’ or death after a month. The participants were unvaccinated and were considered high risk for hospitalisation, due to issues like obesity, diabetes or heart disease. Those who were administered the drug earlier showed comparatively better results. 

Though the news of the new drug has created headlines, the US health administration has stressed the need for absolute vaccination to curb the virus, though effective, easy to available treatments can be used in the future as numbers are also increasing. The current drug which has not been named yet was first identified during the SARS epidemic in 2003. Pfizer’s drug is part of a long family of antiviral drugs known as protease inhibitors, which revolutionised the treatment of HIV and Hepatitis C. 

Editor's Picks

JAANEMAN| MALAYALAM MOVIE |REVIEW|

SUBTLE HEART RENDERING COMEDY, SUFFICIENTLY DRAMATIC, GRIPPING CHAOS AND BITTERSWEET HUMOUR; A HIGH END COCKTAIL OF SCINTILLATING ENSEMBLE CAST AND CHARACTERS, WRITER- DIRECTOR CHIDAMBARAM ENDURES ALL STORMS TO DELIVER A WINNER

Ensemble casts have a unique place in Malayalam cinema.  For decades, a good family drama in Malayalam has always been a good mix of pain, humour, characters, gripping plots and happy endings.  Writer- Director Chidambaram delivers this fine balance in his debut film Jaaneman and creates a new age ensemble cinema for the routine film goer.

Read More

 THINKALAZHCHA NISHCHAYAM | MALAYALAM CINEMA REVIEW |

SATIRE DRIVEN, NON-MELODRAMATIC, FOCUSED, AND METICULOUSLY SCRIPTED; THIS MOVIE IS A WINNER THROUGH AND THROUGH!

How can one dislike a film that entertains throughout? In english, this movie title means ‘The engagement is on monday’.  There is no surprise in the plot line; all of it is revealed in the title.  The story is about the making of an engagement and the joys and troubles involved.  Senna Hegde pulls off a regular story with exceptional craft. The highlight of the film is its climax.  The climax offers no pomp and show, no tearful departures, no melodramatic breakdowns, no revolutions, no rebellions, no glamour, not even the promised engagement.This film is a must watch not because it is extraordinary, but because it is very ordinary, and the brilliance is entirely in the balance the filmmaker maintained throughout.

 

Read More

KURUP|MALAYALAM MOVIE| REVIEW|
KURUP, THE MOVIE; DULQUER’S ATTEMPT TO CONQUER CINEMASCOPE FILMMAKING LEAVES AUDIENCES EMOTIONLESS

THIS PERIOD MOVIE COMES WITH COMPLETE GRANDEUR; GRAND SETS, STYLE, A GOOD CAST, LEAVES NO STONE UNTURNED IN PRODUCTION, BUT FAILS IN ITS EDITING AND COMPOSITION. DQ DOES NOT BECOME KURUP, KURUP BECOMES DQ. 

Dulquer remains Dulquer, we recognize him and his methods in all his movies and he repeats himself once again.  The actor lacks gravitas in his dialogue delivery and intonation.  Can style and glamour make up for lack of method acting in a role like this?  Did we expect more?

Read More